LXRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LXRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.
Lexicon Pharmaceuticals's Days Sales Outstanding for the
three
months ended in Dec. 2023 was 86.31.
Lexicon Pharmaceuticals's Days Inventory for the
three
months ended in Dec. 2023 was 467.33.
Lexicon Pharmaceuticals's Days Payable for the
three
months ended in Dec. 2023 was 17223.44.
Therefore, Lexicon Pharmaceuticals's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2023 was -16,669.80.
The historical data trend for Lexicon Pharmaceuticals's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexicon Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Conversion Cycle | Get a 7-Day Free Trial | -829.21 | -433.74 | 250.48 | 55.14 | -51,419.31 |
Lexicon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Conversion Cycle | Get a 7-Day Free Trial | 109.17 | 549.40 | -116,595.40 | -143,299.40 | -16,669.80 |
For the Biotechnology subindustry, Lexicon Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Lexicon Pharmaceuticals's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Lexicon Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 157.34 | + | 1636.06 | - | 53212.71 | |
= | -51,419.31 |
Lexicon Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 86.31 | + | 467.33 | - | 17223.44 | |
= | -16,669.80 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexicon Pharmaceuticals (NAS:LXRX) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Philippe Amouyal | director | C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016 |
Lonnel Coats | director, officer: President and CEO | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Raymond Debbane | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Thomas Garner | officer: SVP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381 |
Jeffrey L Wade | officer: EVP, Gen. Counsel | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Wendy Mcdermott | officer: VP, Human Resources | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Diane E. Sullivan | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Artal International S.c.a. | director, 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Invus Partners, Llc | director, 10 percent owner | 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022 |
Ulys, Llc | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Kiernan Seth | officer: VP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kenneth B. Kassler-taub | officer: SVP, Regulatory & QA | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kristen Alexander | officer: VP, Finance and Accounting | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Craig B Granowitz | officer: SVP, Chief Medical Officer | 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960 |
James F Tessmer | officer: VP, Finance & Acctg | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
From GuruFocus
By sperokesalga sperokesalga • 06-06-2023
By sperokesalga sperokesalga • 05-26-2023
By Marketwired • 08-21-2023
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 10-31-2023
By Marketwired • 08-03-2023
By Marketwired • 10-09-2023
By sperokesalga sperokesalga • 05-10-2023
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 10-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.